AUSTIN, Texas — Behavior Labs announced the launch of a new decision intelligence platform designed to provide continuous competitive and market insights for pharmaceutical, biotech, and medical device companies, replacing traditional quarterly review cycles with real-time analysis.
The company said the platform is built around what it calls a “World Model,” a continuously operating system that reflects evolving market conditions for each product. It delivers ongoing intelligence across the product lifecycle, including areas such as patent strategy, biosimilar competition, regulatory pathways, and post-market surveillance.
Behavior Labs said its platform integrates public, regulatory, and commercial data sources from the outset, while allowing organizations to layer in their own internal data within a secure environment. Client data is not used to train models or shared across tenants, the company added.
The launch addresses what Behavior Labs describes as a “ground truth” gap in life sciences organizations, where decision-making at the leadership level can lag behind real-world developments. The company said this disconnect can result in delayed responses to competitive activity, regulatory changes, and emerging safety signals.
“What used to take a team months to compile — competitive landscapes, evidence gaps, pricing scenarios — the platform produces continuously and keeps current. That’s the shift: from quarterly snapshots to daily intelligence,” said Nicholas King, founder and CEO of Behavior Labs. “And the platform compounds its knowledge with every interaction — it doesn’t forget context between meetings, and it doesn’t walk out the door when an employee leaves.”
According to the company, the platform provides tools for competitive monitoring, including tracking regulatory filings, hiring activity, patent developments, and scientific publications. It also supports pricing and market access decisions, medical affairs planning, and lifecycle management strategies, particularly for products approaching loss of exclusivity.
For medical device companies, the platform includes regulatory pathway analysis based on more than 190,000 FDA device clearances, as well as post-market surveillance tools that analyze adverse event reports and complaint data. Additional features include hospital market access tracking and portfolio analytics for large product portfolios.
Behavior Labs said the system aggregates data from sources such as ClinicalTrials.gov, FDA and European Medicines Agency filings, patent databases, payer formularies, and adverse event reporting systems, combining them into unified product profiles.
The platform is available immediately. The company said it is offering a single-product intelligence assessment for organizations evaluating the system, allowing teams to analyze a specific asset without committing to full platform adoption.
